NaturalShrimp is a shell company transitioning from its historical shrimp farming operations to the commercialization of water treatment and aquaculture technologies. The company previously utilized proprietary technology to produce Pacific White shrimp in high-density, inland facilities designed for ecological control. Following a loan default and court-supervised receivership, NaturalShrimp transferred its fixed assets and patents to lenders in May 2025 and ceased all original operations. The company is now licensing and commercializing intellectual property from Hydrenesis, focusing on electrocoagulation-based treatment systems and hydrogen-based water applications. NaturalShrimp is led by David Antelo, who serves as the sole officer and director while also leading Hydrenesis. The company is currently restructuring its legacy liabilities into preferred stock and has not yet generated revenue under its new direction. Its common stock trades on the OTC Expert Market, accessible primarily to professional investors. This pivot represents a fundamental shift from direct aquaculture production to a technology-licensing model aimed at water treatment sectors.